Should I buy or sell Gracell Biotechnologies stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GRCL shares. View GRCL analyst ratings or view top-rated stocks .

What is Gracell Biotechnologies' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price. View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts .

How have GRCL shares performed in 2023?

Gracell Biotechnologies' stock was trading at $2.30 on January 1st, 2023. Since then, GRCL stock has increased by 123.0% and is now trading at $5.13. View the best growth stocks for 2023 here .

When is Gracell Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our GRCL earnings forecast .

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.16.

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an IPO on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (14.97%), Hudson Bay Capital Management LP (2.75%), Pivotal bioVenture Partners Investment Advisor LLC (1.89%), Adage Capital Partners GP L.L.C. (1.17%), Schonfeld Strategic Advisors LLC (1.04%) and Barclays PLC (0.43%).

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Gracell Biotechnologies Stock Price, News & Analysis (NASDAQ:GRCL)

$5.13

+0.15 (+3.01%)

(As of 12/7/2023 ET)

Compare

Today's Range: $4.90
▼
$5.18
50-Day Range: $2.43
▼
$5.40
52-Week Range: $1.40
▼
$6.99

Volume: 324,944 shs
Average Volume: 351,803 shs
Market Capitalization: $372.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Gracell Biotechnologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 166.4% Upside
$13.67 Price Target
Short Interest: Healthy
1.29% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.46
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.92) to ($0.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

550th out of 960 stocks

Pharmaceutical Preparations Industry

205th out of 381 stocks

3.5

Analyst's Opinion

Consensus Rating
Gracell Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, Gracell Biotechnologies has a forecasted upside of 166.4% from its current price of $5.13.
Amount of Analyst Coverage
Gracell Biotechnologies has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.29% of the float of Gracell Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
Gracell Biotechnologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Gracell Biotechnologies has recently increased by 2.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Gracell Biotechnologies does not currently pay a dividend.
Dividend Growth
Gracell Biotechnologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRCL.

2.5

News and Social Media Coverage

News Sentiment
Gracell Biotechnologies has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Gracell Biotechnologies this week, compared to 1 article on an average week.
Search Interest
7 people have searched for GRCL on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Gracell Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gracell Biotechnologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.00% of the stock of Gracell Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Gracell Biotechnologies are expected to decrease in the coming year, from ($0.92) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gracell Biotechnologies is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gracell Biotechnologies is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gracell Biotechnologies has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.

GRCL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRCL Stock News Headlines

December 2, 2023 | finance.yahoo.com

Institutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the company

December 2, 2023 | americanbankingnews.com

Gracell Biotechnologies Inc. (NASDAQ:GRCL) Receives Average Recommendation of "Buy" from Brokerages

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 29, 2023 | americanbankingnews.com

Evercore ISI Initiates Coverage on Gracell Biotechnologies (NASDAQ:GRCL)

November 29, 2023 | markets.businessinsider.com

Buy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy Advancements

November 28, 2023 | msn.com

Evercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform Recommendation

November 27, 2023 | marketwatch.com

Gracell Biotechnologies Shares Rise 9%, FDA Clears Application for Lupus Treatment

November 27, 2023 | markets.businessinsider.com

Gracell Biotechnologies: FDA Clears IND Application For Phase 1/2 Trial Of FasTCAR-T GC012F

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 27, 2023 | finance.yahoo.com

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

November 23, 2023 | finance.yahoo.com

What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?

November 23, 2023 | finance.yahoo.com

Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?

November 16, 2023 | finanznachrichten.de

Gracell Biotechnologies Inc.: Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

November 16, 2023 | finance.yahoo.com

Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

November 14, 2023 | markets.businessinsider.com

Positive Outlook for Gracell Biotechnologies: Promising Translational Data and Financial Stability Backs Buy Rating

November 14, 2023 | markets.businessinsider.com

Gracell Biotechnologies: Promising Developments in Systemic Lupus Erythematosus Treatment Augment Buy Rating

November 14, 2023 | finance.yahoo.com

Q3 2023 Gracell Biotechnologies Inc Earnings Call

November 13, 2023 | finanznachrichten.de

Gracell Biotechnologies Inc.: Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

November 10, 2023 | benzinga.com

A Preview Of Gracell Biotechnologies's Earnings

November 9, 2023 | finance.yahoo.com

Should You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings?

November 8, 2023 | finance.yahoo.com

Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program

November 2, 2023 | finance.yahoo.com

Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition

October 31, 2023 | finance.yahoo.com

Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

October 19, 2023 | msn.com

Stifel Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Buy Recommendation

October 19, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Gracell Biotechnologies

September 27, 2023 | finance.yahoo.com

Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

See More Headlines

Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/11/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GRCL
CUSIP: N/A
CIK: 1826492
Web: www.gracellbio.com
Phone: 86-512-6262-6701
Fax: N/A
Employees: 314
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.67
High Stock Price Target: $20.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +166.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -37.40%
Return on Assets: -31.24%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 7.73
Quick Ratio: 7.73

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 6,213.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.95 per share
Price / Book: 1.74

Miscellaneous

Outstanding Shares: 72,678,000
Free Float: 52,328,000
Market Cap: $372.84 million
Optionable: Not Optionable
Beta: -0.77

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Wei Cao BM (Age 64)
Ph.D., Founder, Chairman & CEO
Dr. Yili Xie M.B.A. (Age 52)
Ph.D., Chief Financial Officer
Dr. Samuel Suhua Zhang M.B.A. (Age 55)
Ph.D., Chief Business Officer
Dr. Wendy Li M.D. (Age 64)
Chief Medical Officer
Ms. Erin Li
Executive Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GRCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GRCL shares.
View GRCL analyst ratings or view top-rated stocks.
What is Gracell Biotechnologies' stock price target for 2024?: 6 Wall Street research analysts have issued 1 year price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price.
View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts.
How have GRCL shares performed in 2023?: Gracell Biotechnologies' stock was trading at $2.30 on January 1st, 2023. Since then, GRCL stock has increased by 123.0% and is now trading at $5.13.
View the best growth stocks for 2023 here.
When is Gracell Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our GRCL earnings forecast.

How were Gracell Biotechnologies' earnings last quarter?: Gracell Biotechnologies Inc. (NASDAQ:GRCL) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.16.
When did Gracell Biotechnologies IPO?: (GRCL) raised $150 million in an IPO on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.
Who are Gracell Biotechnologies' major shareholders?: Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (14.97%), Hudson Bay Capital Management LP (2.75%), Pivotal bioVenture Partners Investment Advisor LLC (1.89%), Adage Capital Partners GP L.L.C. (1.17%), Schonfeld Strategic Advisors LLC (1.04%) and Barclays PLC (0.43%).
How do I buy shares of Gracell Biotechnologies?: Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GRCL) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial